Glenmark Pharmaceuticals Ltd.

MUMBAI, India, November 4, 2011 - ~ SCRIP, the world's leading pharmaceutical magazine crowns Glenmark with'Best Company in Emerging Markets'and 'Best Overall Pipeline'recognitions SCRIP, a leading global pharmaceutical and biotech news publication, honoured Glenmark with two global recognitions, for its business excellence and innovative R & D capabilities.

JAIPUR, India, September 20, 2011 - ~ To address the issue of High Infant & Child Mortality by focusing on: Reducing Malnutrition Increasing Immunization Promoting good hygiene practices among pregnant mothers and caregivers ~ Over 150 villages near Jaipur will be adopted by the foundation ~ Glenmark Foundation, the Corporate Social Responsibility (CSR) arm of Glenmark Pharmaceuticals has announced the launch of its flagship programme, 'Project Kavach' - 'Healthy Children, Healthier World' in the state of Rajasthan.

MUMBAI, August 10, 2011 - Revamilast is a PDE4 inhibitor, under development for Asthma, Rheumatoid Arthritis and other inflammatory disorders The molecule successfully completed pre-clinical trials and Phase I studies Phase I studies on healthy volunteers were carried out mainly in the UK Glenmark has initiated global Phase IIb studies for both indications in Europe and Asia Huge unmet medical need as globally they are over 300 million Asthma patients and over 20 million Rheumatoid Arthritis patients Glenmark Pharmaceuticals today announced that its Novel Chemical Entity "Revamilast" (GRC 4039) has initiated Phase IIb human dose range finding trials globally.

MUMBAI, India, May 16, 2011 - Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announced today that it has entered into an agreement with Sanofi to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn's Disease and other inflammatory conditions.

MUMBAI, India, March 3, 2011 - Glenmark Generics Inc., USA (GGI), the United States subsidiary of Glenmark Generics Limited (GGL), announced they have been granted final approval for their Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (U.S.